

Resource Summary Report

Generated by SPARC SAWG on Sep 13, 2026

National Cell Repository for Alzheimer's Disease

RRID:SCR_007313

Type: Tool

Proper Citation

National Cell Repository for Alzheimer's Disease (RRID:SCR_007313)

Resource Information

URL: <http://ncrad.iu.edu/>

Proper Citation: National Cell Repository for Alzheimer's Disease (RRID:SCR_007313)

Description: Cell repository for Alzheimer's disease that collects and maintains biological specimens and associated data. Its data is derived from large numbers of genetically informative, phenotypically well-characterized families with multiple individuals affected with Alzheimer's disease, as well as individuals for case-control studies.

Abbreviations: NCRAD

Resource Type: biomaterial supply resource, material resource, tissue bank

Keywords: gene, alzheimers disease, dementia, dna, late onset, memory loss, phenotypic data, research study, clinical data, plasma, serum, rna, brain tissue, family history, blood

Related Condition: Alzheimer's disease, Late-onset Alzheimer's disease, Dementia, Memory loss

Funding: NIA ;
NIH Blueprint for Neuroscience Research

Availability: Public, Application required for genetic research

Resource Name: National Cell Repository for Alzheimer's Disease

Resource ID: SCR_007313

Alternate IDs: nif-0000-00178

Record Creation Time: 20220129T080241+0000

Record Last Update: 20260912T200147+0000

Ratings and Alerts

No rating or validation information has been found for National Cell Repository for Alzheimer's Disease.

No alerts have been found for National Cell Repository for Alzheimer's Disease.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Carrillo MC, et al. (2026) The partnership between the Alzheimer's Association, Alzheimer's Disease Research Centers (ADRCs), and the National Alzheimer's Coordinating Center (NACC) in advancing Alzheimer's disease research and care. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 22(2), e71210.

Qiu Y, et al. (2025) Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's disease. *Alzheimer's research & therapy*, 17(1), 97.

Alosco ML, et al. (2025) Boston University Alzheimer's Disease Research Center Clinical Core: Infrastructure to facilitate research on post-traumatic Alzheimer's disease and related dementias. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(9), e70654.

Ren Y, et al. (2025) Utilization of precision medicine digital twins for drug discovery in Alzheimer's disease. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 22(3), e00553.

Oomens JE, et al. (2025) The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(11), e70880.

Gildengers AG, et al. (2025) The LATTICE Study: Design of a pilot feasibility randomized controlled trial of lithium to delay cognitive decline in mild cognitive impairment. *Alzheimer's & dementia (New York, N. Y.)*, 11(2), e70112.

Huang YN, et al. (2025) Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(8), e70579.

Sheth U, et al. (2025) Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders. *Molecular neurodegeneration*, 20(1), 30.

Riviere ME, et al. (2024) Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ϵ 4 homozygotes. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(3), 1839.

Chen A, et al. (2024) Performance of SOBA-AD blood test in discriminating Alzheimer's disease patients from cognitively unimpaired controls in two independent cohorts. *Scientific reports*, 14(1), 7946.

Jain L, et al. (2024) ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(1), 549.

Tariot PN, et al. (2024) Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(11), 7745.

Carraro C, et al. (2024) Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs. *Frontiers in molecular neuroscience*, 17, 1414886.

Bowles KR, et al. (2023) Development of MAPT S305 mutation models exhibiting elevated 4R tau expression, resulting in altered neuronal and astrocytic function. *bioRxiv : the preprint server for biology*.

Krebs CE, et al. (2023) Author Guide for Addressing Animal Methods Bias in Publishing. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 10(30), e2303226.

Slawsky ED, et al. (2022) Neighborhood greenspace exposure as a protective factor in dementia risk among U.S. adults 75 years or older: a cohort study. *Environmental health : a global access science source*, 21(1), 14.

Fabrizio C, et al. (2021) Artificial Intelligence for Alzheimer's Disease: Promise or Challenge? *Diagnostics (Basel, Switzerland)*, 11(8).

Mishra R, et al. (2020) The Application of Artificial Intelligence in the Genetic Study of Alzheimer's Disease. *Aging and disease*, 11(6), 1567.

Lew AR, et al. (2018) Copy Number Variations in Adult-onset Neuropsychiatric Diseases. *Current genomics*, 19(6), 420.

Jun G, et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. *Molecular psychiatry*, 21(1), 108.